Literature DB >> 12954055

Synthesis and discovery of macrocyclic polyoxygenated bis-7-azaindolylmaleimides as a novel series of potent and highly selective glycogen synthase kinase-3beta inhibitors.

Gee-Hong Kuo1, Catherine Prouty, Alan DeAngelis, Lan Shen, David J O'Neill, Chandra Shah, Peter J Connolly, William V Murray, Bruce R Conway, Peter Cheung, Lori Westover, Jun Z Xu, Richard A Look, Keith T Demarest, Stuart Emanuel, Steven A Middleton, Linda Jolliffe, Mary Pat Beavers, Xin Chen.   

Abstract

Attempts to design the macrocyclic maleimides as selective protein kinase C gamma inhibitors led to the unexpected discovery of a novel series of potent and highly selective glycogen synthase kinase-3beta (GSK-3beta) inhibitors. Palladium-catalyzed cross-coupling reactions were used to synthesize the key intermediates 17 and 22 that resulted in the synthesis of novel macrocycles. All three macrocyclic series (bisindolyl-, mixed 7-azaindoleindolyl-, and bis-7-azaindolylmaleimides) were found to have submicromolar inhibitory potency at GSK-3beta with various degrees of selectivity toward other protein kinases. To gain the inhibitory potency at GSK-3beta, the ring sizes of these macrocycles may play a major role. To achieve the selectivity at GSK-3beta, the additional nitrogen atoms in the indole rings may contribute to a significant degree. Overall, the bis-7-azaindolylmaleimides 28 and 29 exhibited little or no inhibitions to a panel of 50 protein kinases. Compound 29 almost behaved as a GSK-3beta specific inhibitor. Both 28 and 29 displayed good potency in GS cell-based assay. Molecular docking studies were conducted in an attempt to rationalize the GSK-3beta selectivity of azaindolylmaleimides.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12954055     DOI: 10.1021/jm030115o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  11 in total

1.  New leads for selective GSK-3 inhibition: pharmacophore mapping and virtual screening studies.

Authors:  Dhilon S Patel; Prasad V Bharatam
Journal:  J Comput Aided Mol Des       Date:  2006-04-19       Impact factor: 3.686

2.  AAK1 identified as an inhibitor of neuregulin-1/ErbB4-dependent neurotrophic factor signaling using integrative chemical genomics and proteomics.

Authors:  Letian Kuai; Shao-En Ong; Jon M Madison; Xiang Wang; Jeremy R Duvall; Timothy A Lewis; Catherine J Luce; Sean D Conner; David A Pearlman; John L Wood; Stuart L Schreiber; Steven A Carr; Edward M Scolnick; Stephen J Haggarty
Journal:  Chem Biol       Date:  2011-07-29

3.  Pharmacophore-based screening and drug repurposing exemplified on glycogen synthase kinase-3 inhibitors.

Authors:  Luminita Crisan; Sorin Avram; Liliana Pacureanu
Journal:  Mol Divers       Date:  2017-01-21       Impact factor: 2.943

4.  Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.

Authors:  Ki Hwan Kim; Irina Gaisina; Franck Gallier; Denise Holzle; Sylvie Y Blond; Andrew Mesecar; Alan P Kozikowski
Journal:  J Mol Model       Date:  2009-05-14       Impact factor: 1.810

5.  The marine natural-derived inhibitors of glycogen synthase kinase-3beta phenylmethylene hydantoins: In vitro and in vivo activities and pharmacophore modeling.

Authors:  Mohammad A Khanfar; Bilal Abu Asal; Mudit Mudit; Amal Kaddoumi; Khalid A El Sayed
Journal:  Bioorg Med Chem       Date:  2009-06-27       Impact factor: 3.641

Review 6.  Glycogen synthase kinase 3: more than a namesake.

Authors:  Geetha Vani Rayasam; Vamshi Krishna Tulasi; Reena Sodhi; Joseph Alex Davis; Abhijit Ray
Journal:  Br J Pharmacol       Date:  2009-03-04       Impact factor: 8.739

7.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.

Authors:  Hagit Eldar-Finkelman; Ana Martinez
Journal:  Front Mol Neurosci       Date:  2011-10-31       Impact factor: 5.639

8.  Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models.

Authors:  Thomas Kramer; Boris Schmidt; Fabio Lo Monte
Journal:  Int J Alzheimers Dis       Date:  2012-07-22

9.  4-Aminoethylamino-emodin--a novel potent inhibitor of GSK-3beta--acts as an insulin-sensitizer avoiding downstream effects of activated beta-catenin.

Authors:  Rolf Gebhardt; Katja S Lerche; Frank Götschel; Robert Günther; Jens Kolander; Lars Teich; Sebastian Zellmer; Hans-Jörg Hofmann; Kurt Eger; Andreas Hecht; Frank Gaunitz
Journal:  J Cell Mol Med       Date:  2009-10-03       Impact factor: 5.310

10.  Insights into the interactions between maleimide derivates and GSK3β combining molecular docking and QSAR.

Authors:  Luisa Quesada-Romero; Karel Mena-Ulecia; William Tiznado; Julio Caballero
Journal:  PLoS One       Date:  2014-07-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.